Showing results (131-140 of 586) with videos related to

Sort By:
Pageof 59
Vaccine|April 4, 2022
Benefit-risk assessment of COVID-19 vaccine, mRNA (Comirnaty) for age 16-29 yearsPatrick R Funk, Osman N Yogurtcu, Richard A Forshee, et al.
Vaccine: X|June 16, 2023
Benefit-risk assessment of Covid-19 vaccine, MRNA (MRNA-1273) for males age 18-64 yearsOsman N Yogurtcu, Patrick R Funk, Richard A Forshee, et al.
Journal of the American College of Cardiology|October 2, 2002
Patient outcomes after fibrinolytic therapy for acute myocardial infarction at hospitals with and without coronary revascularization capabilityRajendra H Mehta, Douglas A Criger, Christopher B Granger, et al.
Journal of Thrombosis and Thrombolysis|April 9, 2005
Antibodies to platelet factor 4/heparin are associated with elevated endothelial cell activation markers in patients with acute coronary ischemic syndromesMary Ann Mascelli, Efthymios N Deliargyris, Lakshmi V Damaraju, et al.
American Heart Journal|April 29, 2006
Multifaceted intervention to promote beta-blocker use in heart failureNancy M Allen LaPointe, Elizabeth R DeLong, Anita Chen, et al.
JAMA|September 14, 2006
Peer-reviewed publication of clinical trials completed for pediatric exclusivityDaniel K Benjamin, Philip Brian Smith, M Dianne Murphy, et al.
Cardiac Electrophysiology Review|January 24, 2004
Significance of atrial fibrillation during acute myocardial infarction, and its current management: insights from the GUSTO-3 trialCheuk-Kit Wong, Harvey D White, Robert G Wilcox, et al.
Journal of the American College of Cardiology|October 30, 2007
Long-term outcome and its predictors among patients with ST-segment elevation myocardial infarction complicated by shock: insights from the GUSTO-I trialMandeep Singh, Jennifer White, David Hasdai, et al.
Clinical Pharmacology and Therapeutics|April 25, 2021
When Can We Rely on Real-World Evidence to Evaluate New Medical Treatments?Gregory E Simon, Richard Platt, Jonathan H Watanabe, et al.
Pageof 59